Feng Tian, Ambrx CEO (Ambrx)
After 5 quiet years, a former Scripps spinout raises $200M and announces plans to try again at an IPO
The first time San Diego biotech Ambrx tried to go public in 2014, they failed and the company’s board switched to a radically different strategy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
